Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents

Vaccine

Volumn 32, Issue 43, 2014, Pages 5722-5729

  Wong, Gary ^a,b   Audet, Jonathan ^a,b   Fernando, Lisa ^a   Fausther Bovendo, Hugues ^a   Alimonti, Judie B ^a   Kobinger, Gary P ^a,b,c   Qiu, Xiangguo ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ebola; Guinea pig, Mouse; Long term immunity; Vaccine; Vesicular stomatitis virus

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS VACCINE; VIRUS GLYCOPROTEIN; VIRUS VACCINE; EBOLA VACCINE; ENVELOPE GLYCOPROTEIN, EBOLA VIRUS; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EXPERIMENTAL GUINEA PIG; FEMALE; HUMORAL IMMUNITY; LETHAL DOSE; NONHUMAN; RODENT MODEL; SURVIVAL TIME; SURVIVOR; VACCINATION; WEIGHT CHANGE; WEIGHT REDUCTION; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; BLOOD; GUINEA PIG; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; VESICULOVIRUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; EBOLA VACCINES; EBOLAVIRUS; FEMALE; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; IMMUNOGLOBULIN G; MICE, INBRED BALB C; VESICULOVIRUS; VIRAL ENVELOPE PROTEINS;

EID: 84908457744     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.028     Document Type: Article

References (39)

1. CDC.gov. Chronology of Ebola hemorrhagic fever outbreaks, 2014 [accessed 08.08.14].
2. Leroy E.M., Kumulungui B., Pourrut X., Rouquet P., Hassanin A., Yaba P., et al. Fruit bats as reservoirs of Ebola virus. Nature 2005, 438:575-576.
3. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408:605-609.
4. Sullivan N.J., Geisbert T.W., Geisbert J.B., Shedlock D.J., Xu L., Lamoreaux L., et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006, 3:e177.
5. Warfield K.L., Swenson D.L., Olinger G.G., Kalina W.V., Aman M.J., Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007, 196(Suppl 2):S430-S437.
6. Bukreyev A., Rollin P.E., Tate M.K., Yang L., Zaki S.R., Shieh W.J., et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007, 81:6379-6388.
7. Blaney J.E., Marzi A., Willet M., Papaneri A.B., Wirblich C., Feldmann F., et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 2013, 9:e1003389.
8. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005, 11:786-790.
9. Feldmann H., Jones S.M., Daddario-DiCaprio K.M., Geisbert J.B., Stroher U., Grolla A., et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007, 3:e2.
10. Qiu X., Fernando L., Alimonti J.B., Melito P.L., Feldmann F., Dick D., et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS One 2009, 4:e5547.
11. Geisbert T.W., Hensley L.E., Geisbert J.B., Leung A., Johnson J.C., Grolla A., et al. Post-exposure treatment of Marburg virus infection. Emerg Infect Dis 2010, 16:1119-1122.
12. Geisbert T.W., Daddario-DiCaprio K.M., Williams K.J., Geisbert J.B., Leung A., Feldmann F., et al. Recombinant vesicular stomatitis virus vector mediates post-exposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008, 82:5664-5668.
13. Geisbert T.W., Geisbert J.B., Leung A., Daddario-DiCaprio K.M., Hensley L.E., Grolla A., et al. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol 2009, 83:7296-7304.
14. Gunther S., Feldmann H., Geisbert T.W., Hensley L.E., Rollin P.E., Nichol S.T., et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011, 204(Suppl 3):S785-S790.
15. Brandly C.A., Hanson R.P. Epizootiology of vesicular stomatitis. Am J Public Health Nations Health 1957, 47:205-209.
16. Johnson K.M., Vogel J.E., Peralta P.H. Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am J Trop Med Hyg 1966, 15:244-246.
17. Brody J.A., Fischer G.F., Peralta P.H. Vesicular stomatitis virus in Panama. Human serologic patterns in a cattle raising area. Am J Epidemiol 1967, 86:158-161.
18. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 2005, 340:174-182.
19. Schwartz J.A., Buonocore L., Suguitan A.L., Silaghi A., Kobasa D., Kobinger G., et al. Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J Virol 2010, 84:4611-4618.
20. Prescott J., DeBuysscher B.L., Brown K.S., Feldmann H. Long-term single-dose efficacy of a vesicular stomatitis virus-based Andes virus vaccine in Syrian hamsters. Viruses 2014, 6:516-523.
21. Mire C.E., Geisbert J.B., Agans K.N., Satterfield B.A., Versteeg K.M., Fritz E.A., et al. Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS One 2014, 9:e94355.
22. Marzi A., Engelmann F., Feldmann F., Haberthur K., Shupert W.L., Brining D., et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A 2013, 110:1893-1898.
23. Wong G., Richardson J.S., Pillet S., Patel A., Qiu X., Alimonti J., et al. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012, 4:158ra46.
24. Storer J.B. Longevity and gross pathology at death in 22 inbred mouse strains. J Gerontol 1966, 21:404-409.
25. Jones S.M., Stroher U., Fernando L., Qiu X., Alimonti J., Melito P., et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007, 196(Suppl 2):S404-S412.
26. Qiu X., Audet J., Wong G., Fernando L., Bello A., Pillet S., et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep 2013, 3:3365.
27. Ksiazek T.G., Rollin P.E., Williams A.J., Bressler D.S., Martin M.L., Swanepoel R., et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999, 179(Suppl 1):S177-S187.
28. Ksiazek T.G., West C.P., Rollin P.E., Jahrling P.B., Peters C.J. ELISA for the detection of antibodies to Ebola viruses. J Infect Dis 1999, 179(Suppl 1):S192-S198.
29. Wauquier N., Becquart P., Gasquet C., Leroy E.M. Immunoglobulin G in Ebola outbreak survivors. Gabon. Emerg Infect Dis 2009, 15:1136-1137.
30. Sobarzo A., Ochayon D.E., Lutwama J.J., Balinandi S., Guttman O., Marks R.S., et al. Persistent immune responses after Ebola virus infection. N Engl J Med 2013, 369:492-493.
31. Sobarzo A., Groseth A., Dolnik O., Becker S., Lutwama J.J., Perelman E., et al. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan Ebola virus (Gulu). J Infect Dis 2013, 208:299-309.
32. ClinicalTrials.gov. Experimental vaccine for prevention of Ebola virus infection, 2014 [accessed 08.08.14].
33. ClinicalTrials.gov. Experimental Ebola vaccine trial, 2014 [accessed 08.08.14].
34. ClinicalTrials.gov. Ebola and Marburg virus vaccines, 2014 [accessed 08.08.14].
35. ClinicalTrials.gov. Evaluating an Ebola and a Marburg vaccine in Uganda, 2014 [accessed 08.08.08].
36. Garbutt M., Liebscher R., Wahl-Jensen V., Jones S., Moller P., Wagner R., et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004, 78:5458-5465.
37. Bray M., Davis K., Geisbert T., Schmaljohn C., Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998, 178:651-661.
38. Connolly B.M., Steele K.E., Davis K.J., Geisbert T.W., Kell W.M., Jaax N.K., et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999, 179(Suppl 1):S203-S217.
39. Nakayama E., Yokoyama A., Miyamoto H., Igarashi M., Kishida N., Matsuno K., et al. Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin Vaccine Immunol 2010, 17:1723-1728.